Clinical update: new treatments for age-related macular degeneration.
Wong
Tien Y
TY
Centre for Eye Research, University of Melbourne, Melbourne 3002, Victoria, Australia; Singapore Eye Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: twong@unimelb.edu.au.
Liew
Gerald
G
Centre for Vision Research, University of Sydney, NSW, Australia.
Mitchell
Paul
P
Centre for Vision Research, University of Sydney, NSW, Australia.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068258:Bevacizumab; D003327:Coronary Disease / Q000139:chemically induced; D006207:Half-Life; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D000069579:Ranibizumab; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab